Emera Inc.(EMA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

EMA Emera Inc.

交易中 05-08 09:53:34 EDT

52.79

+0.60

+1.14%

最高53.38	最低52.67	成交量4.24万
今开52.96	昨收52.19	日振幅1.36%
总市值161.41亿	流通市值160.99亿	总股本3.06亿
成交额224.59万	换手率0.01%	流通股本3.05亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":52.785,"timestamp":1778248389442,"preClose":52.19,"halted":0,"volume":42428,"delay":0,"changeRate":0.011400651465798025,"floatShares":305000000,"shares":305783111,"eps":2.465138,"marketStatus":"交易中","change":0.595,"latestTime":"05-08 09:53:34 EDT","open":52.96,"high":53.38,"low":52.67,"amount":2245868.6052039997,"amplitude":0.013604,"askPrice":52.77,"askSize":300,"bidPrice":52.67,"bidSize":100,"shortable":3,"etf":0,"ttmEps":2.465138,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1778270400000},"marketStatusCode":2,"adr":0,"exchange":"NYSE","adjPreClose":52.19,"dividendRate":0.040001,"preHourTrading":{"tag":"盘前","latestPrice":53.84,"preClose":52.19,"latestTime":"08:21 EDT","volume":2,"amount":107.68,"timestamp":1778242903435,"change":1.65,"changeRate":0.031615,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":52.19,"preClose":52.19,"latestTime":"17:41 EDT","volume":21787,"amount":1136535.915,"timestamp":1778190093722,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.782546,"impliedVol":0.2268,"impliedVolPercentile":0.6635},"requestUrl":"/m/hq/s/EMA","defaultTab":"news","newsList":[{"id":"1185761853","title":"财报前瞻｜Emera Inc.本季度营收预计增35.49%，盈利质量成看点","url":"https://stock-news.laohu8.com/highlight/detail?id=1185761853","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185761853?lang=zh_cn&edition=full","pubTime":"2026-05-01 08:17","pubTimestamp":1777594630,"startTime":"0","endTime":"0","summary":"Emera Inc.将于2026年05月08日公布最新季度业绩，市场关注营收增速与成本控制的落地情况。根据一致预期，本季度Emera Inc.营收预计为30.09亿加元，同比增长35.49%；调整后每股收益预计为1.15加元，同比增长15.55%；息税前利润预计为7.02亿加元，同比增长7.05%；当前一致预期未提供本季度毛利率及净利润或净利率的具体预测。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Emera Inc.本季度营收预计增35.49%，盈利质量成看点","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627213629","title":"罗氏获欧洲监管机构反馈后，启动Elevidys基因疗法新研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2627213629","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627213629?lang=zh_cn&edition=full","pubTime":"2026-04-16 20:44","pubTimestamp":1776343440,"startTime":"0","endTime":"0","summary":"罗氏公司周四宣布，在收到欧洲药品监管机构的反馈后，将针对其基因疗法 Elevidys 启动一项晚期临床试验。该疗法用于治疗杜氏肌营养不良症，由罗氏与美国 Sarepta Therapeutics 公司合作研发。此前，因两例患者死亡事件与该疗法相关而引发审查，这款药物去年未能获得欧洲药品管理局的批准。Elevidys 目前已在 9 个国家获批用于可自主行走、确诊携带 DMD 基因突变的男孩，其中包括美国。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-16/doc-inhuszrw2800982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624593383","title":"港股异动 | 和誉-B(02256)盘中涨近10% FGFR4抑制剂依帕戈替尼获EMA授予孤儿药资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2624593383","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624593383?lang=zh_cn&edition=full","pubTime":"2026-04-01 15:57","pubTimestamp":1775030256,"startTime":"0","endTime":"0","summary":"消息面上，和誉宣布，其自主研发的高选择性小分子FGFR4抑制剂依帕戈替尼已获得欧洲药品管理局授予的孤儿药资格，用于治疗肝细胞癌。目前，依帕戈替尼正在全球多地开展临床研究，此次获EMA授予ODD，将为该产品在欧洲的临床开发、注册申报与商业化进程提供有力支持。除本次获得EMA孤儿药资格外，依帕戈替尼此前还分别获得了美国食品药品监督管理局授予的ODD和快速通道资格认定，以及中国国家药品监督管理局授予的突破性疗法认定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2778985437.USD","LU2476274720.SGD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","LU2488822045.USD","BK4588","EMA","IE00B543WZ88.USD","02256","LU2476274308.USD","BK1161","BK4081","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623581546","title":"和誉-B(02256)：FGFR4抑制剂依帕戈替尼获EMA授予孤儿药资格，用于治疗肝细胞癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2623581546","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623581546?lang=zh_cn&edition=full","pubTime":"2026-03-31 20:32","pubTimestamp":1774960347,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，公司附属公司上海和誉生物医药科技有限公司宣布，其自主研发的高选择性口服小分子FGFR4抑制剂依帕戈替尼已获得欧洲药品管理局授予的孤儿药资格，用于治疗肝细胞癌。目前，依帕戈替尼正在全球多地开展临床研究，此次获EMA授予ODD，将为该产品在欧洲的临床开发、注册申报与商业化进程提供有力支持。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423262.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","IE00B543WZ88.USD","LU2488822045.USD","EMA","BK1161","IE00BPRC5H50.USD","BK4081","IE00B5MMRT66.SGD","LU2476274720.SGD","LU2476274308.USD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616376696","title":"韩国与新加坡启动自贸协定升级谈判并签署核电合作备忘录","url":"https://stock-news.laohu8.com/highlight/detail?id=2616376696","media":"核电网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616376696?lang=zh_cn&edition=full","pubTime":"2026-03-03 18:22","pubTimestamp":1772533330,"startTime":"0","endTime":"0","summary":"近日，韩国总统李在明对新加坡进行了国事访问，两国就升级韩-兴自由贸易协定及核电合作达成重要共识。韩国产业通商资源部长官与新加坡贸工部代表于3月2日共同签署了《关于启动韩新自贸协定升级谈判的联合宣言》。与此同时，韩国水电与核电公司和新加坡能源市场厅也签署了关于小型模块化反应堆合作的谅解备忘录，这标志着韩国核电企业首次与新加坡政府机构在核电领域建立正式合作关系。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303202141a69d90f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303202141a69d90f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4606","BK4081","NLR","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616698376","title":"百奥泰：Usymro（乌司奴单抗注射液）获得英国 MHRA 上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2616698376","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616698376?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:33","pubTimestamp":1772526786,"startTime":"0","endTime":"0","summary":"格隆汇3月3日丨百奥泰公布，公司于近日收到了英国药品和健康产品管理局签发的关于Usymro上市批准通知。截至本公告披露日，BAT2206已获得美国FDA、欧洲 EMA 和英国 MHRA 批准上市，美国注册商品名称为STARJEMZA，欧洲注册商品名称为 Usymro；已向中国 NMPA 递交上市许可申请，目前正在评审中。Usymro获得英国 MHRA 上市批准后可在英国进行销售，公司海外销售产品品类得到进一步扩充，将进一步提升公司产品的国际影响力，有望对公司长期经营业绩产生积极影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303163601a445ce72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303163601a445ce72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614085473","title":"复宏汉霖(02696)：帕妥珠单抗生物类似药HLX11(重组抗HER2结构域II人源化单克隆抗体注射液)获欧洲药品管理局(EMA)人用医药产品委员会(CHMP)积极审评意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2614085473","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614085473?lang=zh_cn&edition=full","pubTime":"2026-02-27 22:27","pubTimestamp":1772202451,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，HLX11获EMA人用医药产品委员会积极审评意见，推荐批准HLX11的上市许可申请。倘若获得EC批准，HLX11的集中上市许可将在所有欧盟成员国及欧洲经济区国家冰岛、列支敦士登和挪威生效。HLX11是本公司自主研发的帕妥珠单抗生物类似药。2024年12月，HLX11的上市注册申请获国家药品监督管理局受理。2025年3月，HLX11的上市许可申请获欧洲药品管理局受理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4087","159938","BK4081","EMA","HK0000320264.USD","02696","HK0000320223.HKD","BK1574","09939","BK1161","HK0000306701.USD","HK0000165453.HKD","BK1515","HK0000306685.HKD","CHMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613797244","title":"百奥泰（688177）披露Gotenfia（戈利木单抗注射液）获欧洲EMA上市批准的公告，2月24日股价下跌0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613797244","media":"中金财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613797244?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:41","pubTimestamp":1771929669,"startTime":"0","endTime":"0","summary":"百奥泰生物制药股份有限公司近日披露公告，公司收到欧洲药品管理局通知，其开发的戈利木单抗注射液已获EMA上市批准。BAT2506是依据NMPA、FDA和EMA指导原则开发的生物类似药，目前上市申请已获NMPA、FDA及巴西国家卫生监督局受理。该批准有望对公司长期经营业绩产生积极影响，但未来可能面临激烈市场竞争。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260224/32024193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["EMA","BK0239","688177","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189502436","title":"财报前瞻｜Emera Inc.本季度营收预计降52.39%，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1189502436","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189502436?lang=zh_cn&edition=full","pubTime":"2026-02-16 10:14","pubTimestamp":1771208088,"startTime":"0","endTime":"0","summary":"Emera Inc.将于2026年02月23日美股盘前发布最新季度财报，市场关注营收与每股收益的同比下滑幅度及业务结构变化。市场一致预期显示，本季度Emera Inc.营收预计为9.66亿美元，同比下降52.39%；调整后每股收益预计为0.56美元，同比下降27.14%；息税前利润预计为2.11亿美元，同比下降72.86%。上季度Emera Inc.营收21.06亿美元，同比增长16.87%；毛利率44.06%；归属母公司净利润2.47亿美元，净利率11.73%，净利润环比增长60.39%；调整后每股收益0.88美元，同比增长8.64%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Emera Inc.本季度营收预计降52.39%，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589334696","title":"乐城引进帕西生长激素注射液 为GHD患儿提供新选择","url":"https://stock-news.laohu8.com/highlight/detail?id=2589334696","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589334696?lang=zh_cn&edition=full","pubTime":"2025-12-08 18:40","pubTimestamp":1765190402,"startTime":"0","endTime":"0","summary":"今年1月，诺和诺德长效生长激素——帕西生长激素注射液作为临床急需药物被引入乐城博鳌未来医院(海南省妇女儿童医学中心乐城分院)，并于5月正式投入临床。目前，该药已惠及20余例年龄在4.5至14.5岁之间的生长激素缺乏症(GHD)患儿，为我国GHD患儿提供了新的治疗选择。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20251208/20251208183409_27282.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251208/20251208183409_27282.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378903.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4081","BK4588","IE00BMG7P587.USD","BK4208","LU2346227817.USD","PEG","IE00BD4GTV84.USD","BK4585","EMA","IE00BMG7P694.USD","IE00BD4GTT62.SGD","IE00BMG7P819.SGD","IE00BMG7P926.USD","IE00BD4GTW91.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589519008","title":"港股异动 | 亚盛医药-B(06855)涨超6% 耐立克®POLARIS-1研究获美国FDA和欧洲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589519008","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589519008?lang=zh_cn&edition=full","pubTime":"2025-12-05 09:33","pubTimestamp":1764898401,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B涨超6%，截至发稿，涨5.67%，报64.2港元，成交额1993.31万港元。消息面上，12月5日，亚盛医药-B发布公告，公司原创1类新药奥雷巴替尼联合化疗治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者的全球注册III期临床研究获美国食品药品监督管理局和欧洲药品管理局同意开展。作为耐立克在欧美监管机构获批的第二个全球注册III期研究，POLARIS-1研究在多国家多中心同步入组，将加速耐立克全球特别是欧美市场的上市进程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4081","AAPG","06855","EMA","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589985521","title":"亚盛医药-B(06855)耐立克®一线治疗Ph+ ALL的全球注册III期临床研究获美国FDA和欧洲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589985521","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589985521?lang=zh_cn&edition=full","pubTime":"2025-12-05 08:03","pubTimestamp":1764893004,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，公司原创1类新药奥雷巴替尼联合化疗治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者的全球注册III期临床研究获美国食品药品监督管理局和欧洲药品管理局同意开展。同时，耐立克在Ph+ ALL领域深度布局，针对Ph+ ALL领域的治疗已获《CSCO恶性血液病诊疗指南》连续推荐，并获CDE突破性疗法认定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4585","LU0985320562.USD","BK4081","BK4139","BK4533","LU1699723380.USD","06855","BK4107","ALL","LU1571399168.USD","BK4588","III","EMA","BK1574","LU2355687059.USD","AAPG","BK4134"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.emera.com","stockEarnings":[{"period":"1week","weight":-0.023},{"period":"1month","weight":-0.014},{"period":"3month","weight":0.0571},{"period":"6month","weight":0.0887},{"period":"1year","weight":0.1526},{"period":"ytd","weight":0.0599}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.1098},{"period":"3month","weight":0.0593},{"period":"6month","weight":0.0903},{"period":"1year","weight":0.3037},{"period":"ytd","weight":0.0728}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Emera Inc.于1998年7月23日在加拿大注册成立，是一家北美能源服务提供商，拥有并经营服务成本、费率管制的电力和天然气公用事业组合。该公司最大的业务在佛罗里达州，并在加拿大大西洋省、新墨西哥州和加勒比地区增加了业务。Emera总部位于新斯科舍省哈利法克斯，其业务战略侧重于对其受监管的公用事业、卓越运营和效率进行持续投资，以便为其270万客户可靠地提供能源。公司在受监管公用事业的盈利机会取决于净投资规模、资本结构权益和目标回报，这些都是通过监管建立起来的。","exchange":"NYSE","name":"Emera Inc.","nameEN":"Emera Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Emera Inc.(EMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Emera Inc.(EMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Emera Inc.,EMA,Emera Inc.股票,Emera Inc.股票老虎,Emera Inc.股票老虎国际,Emera Inc.行情,Emera Inc.股票行情,Emera Inc.股价,Emera Inc.股市,Emera Inc.股票价格,Emera Inc.股票交易,Emera Inc.股票购买,Emera Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Emera Inc.(EMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Emera Inc.(EMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}